XENE

As of 2026-10-26, XENE scores 18out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. XENE trades at $35.77, 9% below the band floor.

XENE scores 18 out of 100 on QNTM's five-factor model — a low-conviction reading — at 18 the factor profile is among the weaker names in the universe. Its strongest factor is sentiment at 50 (middling), where analyst and positioning signals are improving, followed by volume at 30. The weakest is value at 0, where valuation looks stretched. Among Healthcare stocks it sits in the lower 2% of Healthcare names by composite.

On valuation, XENE is priced near the floor of its own recent range — the cheap end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 18. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on XENE, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where XENE sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for XENE runs $39.12–$69.75. Current price $35.77 sits 9% below the band floor. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.